Personalized cancer therapy co OncoHost raises $35m
Israeli personalised most cancers treatment developer OncoHost has declared the completion of an oversubscribed $35 million Collection C financing round led by ALIVE Israel HealthTech VC with participation from Leumi Associates, Menora Mivtachim, OurCrowd and other present buyers. ALIVE’s co-founder and general controlling partner Prof. Ari Shamiss has jopined OncoHost’s board.

The funding be utilised to grow OncoHost’s ongoing multicenter PROPHETIC demo which utilizes PROphet, the company’s device finding out-primarily based host response profiling system. The Binyamina-based mostly company’s precision oncology diagnostic resolution is expected to start commercially in the US in the 3rd quarter of 2022.

Leveraging state-of-the-art proteomic investigation and AI-centered host reaction science, OncoHost’s PROphet platform is a individualized, genuine-time, dynamic ‘disease navigator’ that gives early identification of an individual’s responsiveness to cancer therapy, evaluation of treatment method resistance mechanisms, and likely accessible methods to conquer this resistance. Scientific demo benefits have demonstrated PROphet to have remarkably superior precision in evaluating non-small mobile lung cancer (NSCLC) affected person response at a few months, six months and 1 yr. Via one particular blood test pre-therapy, the company’s multi-patented platform also supplies clinicians with potential combination approaches to overcome remedy resistance.

Prof. Shamiss said, “OncoHost supplies significant price to equally most cancers people and their clinicians and it is an honor to have led this transformational funding spherical. With promising and major scientific results, OncoHost’s exceptional strategy can build a brighter and far better long run for the world of precision oncology, maximizing the probability of deciding on the suitable treatment combos and significantly increasing therapeutic benefits for cancer people. We are self-confident that Oncohost is set to come to be a pivotal proteomics market chief in personalised oncology remedy.”

OncoHost CEO Dr. Ofer Sharon additional, “This is OncoHost’s 3rd and most significant investment decision round to date, demonstrating the company’s maturity, reliability and scalability. We are honored to be supported by primary neighborhood and world wide expense funds that understand and help our vision to change the landscape of oncology to a actually customized method and want to be aspect of our journey in revolutionizing most cancers treatment.”

OncoHost carries on to open up extra medical demo web pages all over the planet and will be increasing its analysis to more most cancers indications.

Published by Globes, Israel organization information – en.globes.co.il – on May well 11, 2022.

© Copyright of Globes Publisher Itonut (1983) Ltd., 2022.


